Jefferies Ractchets Numbes on Biogen (BIIB) Higher Post Q2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rebounds after Fed's first rate hike in years as oil, Treasury yields dip
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Biogen (BIIB) Underpromise/Overdeliver Strategy Plays Well on Wall Street
July 25, 2013 10:55 AM EDTLeerink Swann today maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $271. Biogen reported strong Q2 results, with notable strength in Tecfidera. Meanwhile, sales of Tysabri appear to be suffering.
"We believe the strong 2Q13 quarter will lead... More
Biogen Idec, Inc. (BIIB) Tops Q2 EPS by 37c; Issues Solid Guidance
July 25, 2013 7:09 AM EDTBiogen Idec, Inc. (NASDAQ: BIIB) reported Q2 EPS of $2.30, $0.37 better than the analyst estimate of $1.93. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.62 billion.
Biogen Idec, Inc. sees FY2013 EPS of $8.25-$8.50, versus the consensus of $8.22.
Revenue gains were led by the performance of our marketed therapies:
AVONEX® revenues increased 2% year-over-year to $774 million. The total was comprised of $479 million in U.S.... More
